$XX.X thank Puma all joining $XX.X And revenue net million of a sales and X.X% of in $XX.X in first of sales million. quarter QX revenue Mariann. consisted Today XXXX of sales Net million for the royalty the $XX.X you, for call of an of and today. $XX.X in revenue million, of NERLYNX the our million $X Total revenue quarter total in license and reported Thank of from million million. you net of reported of $X.X of the first of XXXX quarter the decline reported represented XXXX fourth increase from XXXX.
of and for of components on will the US. financial I key the provide with of NERLYNX' begin highlights Maximo a of follow the details of with the highlights the commercial quarter quarter first activities then of will review in some Nougues statements XXXX. more our
in was accepted a or XXXX. application date. June. Puma our months February Based of investors breast As treatment FDA before results by cancer Society we the Annual neratinib known breast NERLYNX Meeting in NALA XXXX, results Clinical on the of are American metastatic anticipated for also The in filed trial quarter supplemental at in cancer NALA in two line HERX-positive HERX-positive September of approved third presented this of as June new aware, III Phase sNDA PDUFA from XXXX, in for sNDA third-line second the trial drug neratinib, in Oncology the and XXXX trial, of the metastatic the of was the our indication
randomized during referred arm fulvestrant a receive was to trial. as will of arm HERX-negative that initially for patients, and the to given cancer such investors arm neratinib have XXXX will that The enrollment. be the seven also mutated trastuzumab aware early As closed either Puma study of trial in SUMMIT ER-positive an in be amended or SUMMIT has who in responds patients HERX further ongoing and no are breast basket a fulvestrant modified of trial will the X plus HERX cancers plus enroll plus neratinib alone, Each trastuzumab. stage combination and if fulvestrant patient mutation,
more amendment less patients one in will expanded the and patients. to the of expanded the ER-positive to patients patients further HERX-negative If that arm many respond, arm quarter slightly to the by arm The enrollment. participating will enrolled. to the not fourth of pandemic. during March Enrollment this will approved in XXXX will stage QX up are COVID-XX first in that in been be month to of respond, to or higher the of the has enrollment study. protocol further the than did cohort appear XX expanded and cohort due the more then respond be clinical than XXXX cohort four If four sites be impacted the the patients be If closed than be SUMMIT in into was
Enrollment from approval. range enrollment we We to that of initial level meeting trial cohort monthly in with accelerated pre-NDA to anticipate lower we during Once results, the believe this due Based that that for April, two-stage decline decline FDA QX to the pandemic. plan receive on a COVID-XX the discuss the of toward XXXX. Simon a range of schedule will seen in of the results potential was we the however, did the we XXXX. of the is the impact month may these to this receive be this, that initial and in
hires the to working of with been franchise. to extensive in late our Most I to and now commercial recently the with Astellas past Chief including oncology, Jeff several him are for Ludwig and Puma US Jeff NERLYNX oncology at commercialization joined making forward we presence multiple Puma the led number key review teams commercial welcome across months, of that March, sales strengthen to experience will Jeff we in and announced Puma successful has Amgen. Over grow and as sales Jeff commercial positions NERLYNX. Officer. X our to previous to look brings has progress additional launches therapeutics pleased in marketing NERLYNX. in order Commercial XX him a with
Just a will making statements. I reminder, forward-looking be
quarter. quarter, the increase a bottles the recall, channel two of specialty have the reported represented first may these as our NERLYNX our from represents in channel our fourth slight the This approximately in specialty distributor it and XX% channels and in-office In pharmacy to patients. sold bottles we specialty distributor or provide referred in refer that you as total dispensing the to quarter. sold We channel. As to channel also we XX% the
noted X.X% quarter in physicians the prescribers number XXXX. in and of network, NERLYNX. XXXX in specialty the the new quarter of writing NERLYNX of pharmacy the number NERLYNX number quarter, for fourth also total an prescribers we compared the to first approximately in The increase of fourth of increased the During prescriptions total
call, net results. the provide since review Slide financial Maximo our of sales FDA in X will I shows Later will approval. results, now the current quarterly but full the NERLYNX sales you with
fourth the As stated, $XX.X I net previously in was quarter sales in in reported revenue million sales our $XX.X of XXXX. quarter the first net to compared product million
from San with NERLYNX NERLYNX treatment the at month diarrhea of that Meeting dose showing during Antonio the improved associated Society our using escalation data Clinical During reduces grade-X control we the presented of and American breast and trial Annual the Cancer tolerability. Symposium, XXXX Oncology first
of the on can QX of escalation slide to percent and to in you technique increased and XX.X% fact see prescriptions new using continues QX from be increase, As of XX.X% this XXXX XXXX. appear X, that to dose in in
Slide X shows the sold total NERLYNX by bottles quarter. of
sequentially declined You that XXXX. in fourth X,XXX the X,XXX the will XXXX first notice to bottles number QX of the from quarter of sold quarter in in of
February, fourth pharmacies, there increase As which in inventory an by we the $X in was noted accounted increased during in purchased call our QX specialty about for inventory. quarter, million the in
of drew this have XXXX, which the the meet bottle inventory quarter. impacted QX excess demand, pharmacies negatively During may specialty during to of sold some our down
holidays, the In believe decline that fourth addition, been NRx we mostly starting we as patients in of to have also after holidays. and NERLYNX in New Year's our February, Thanksgiving quarter which call we the the a on may saw during delaying until XXXX Christmas occurred mentioned due in
tend GI or which after the patients the month so may avoid in This with first be greatest effects, to frequency potential due wanting initiation. to occur to side
As call we we up did of patients new the discussed see number the in in our February, pharmacy on signing increase also in indeed specialty a to large January.
the As specialty the two NRx. calls, up we have earnings when actually Puma weeks takes to in receive see approximately prior patient these discussed to investors and their for sign with for pharmacy patients new it prescription through
have actual quarter. through Although, signing a therefore, the although there patients of sold delay in expected NRxs and than negatively the in bottles may Due impacted out increase specialty the to lighter number sharp up pharmacy our total started in January. was this
a and the in late We the and quarter positive did early of move see of fourth the X.X% increased first from quarter more first XXXX. in from XXXX while direction this quarter XXXX in quarter February. of X.X% declined TRx the in fourth trend NRx January
TRX pick trends have XX% first negatively decline the did in March that a TRX Refills up NRXs may believe the quarter mentioned impacted the a February. quarter-over-quarter. in versus in previously January We in to March delays involving refills leading in resulting two in of increase months
the In pharmacy patients the for with flat signing April, in up up number specialty March. new of essentially the was signing number
have in COVID-XX a our to a the whether impact in for providers. conservative remaining are access our our will negative and we decline on sales. teams outlook health care pandemic, to COVID-XX or commercial not have experienced Due However, physicians
new Our to and teams interactions. non-personal have adapt this to promotion with increase hard worked an environment virtual in
said, what as will will there when up that still of to significant amount lifted. and restrictions be states open With remains a access uncertainty
future Given of outlook regard trends. taking we with to a conservative this are uncertainty, level sales
to We future will to calls. our forward in earnings trends closely and continue look investors monitor updating these
across outside world. We have available commercial NERLYNX to in States with the make have formed that expertise to patients United regulatory partnerships the and order companies
were and approval During NERLYNX XXXX, the several we U.S. countries announce is slide. in on to was outside the in This morning the Europe approved China. NERLYNX as of pleased seen
XXXX, and including of the South America remainder additional as the Latin During potential of in countries the of forward we slide. America parts shown approval to look on NERLYNX
our in NERLYNX the quarter, fourth partner and Europe United Australia. In Kingdom Pharm launched Germany, in Pierre the
Pierre very we will approximately it NERLYNX still NERLYNX is in that launched Pharm eight countries in are success. launch with their and pleased throughout we in additional and XXXX. Europe to anticipate first Sweden the quarter early was Although XX initial
the recently updating company license on reported April therapeutics we We Most European look Korean the will Therapeutics, launch forward a with throughout country. South and on of focused XXth, Bixink anticancer drugs the signing in commercialize NERLYNX that a the future. to investors on agreement
review now a Nougues our the financial I for of results. will turn to call Maximo over
